Cite

    Glenis Scadding et al.. “MP29-02*'s advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis.” Clinical and translational allergy, vol. 5, no. 4, 2015, pp. 1–2. http://access.bl.uk/ark:/81055/vdc_100080434925.0x00044a